FDA Ties Brisdelle Approval To Unmet Need For Hormone-Free Therapy
This article was originally published in The Pink Sheet Daily
In an NEJM perspective piece, agency reviewers explain why they believed Noven’s paroxetine for treating hot flashes should come to market despite only “modest” efficacy and an advisory committee’s overwhelming recommendation against approval.
You may also be interested in...
Advisory Committee for Reproductive Health Drugs asks whether FDA standards are too difficult to meet for non-hormonal products like gabapentin and paroxetine after the placebo arms of both drugs’ trials show a strong reduction in vasomotor symptoms.
FDA Advisory Committee on Reproductive Health Drugs votes overwhelmingly against recommending approval of new indication for severe to moderate vasomotor symptoms, saying the modest effect shown was not sufficient.
FDA’s Anesthetic and Analgesic Drug Products Advisory Committee wants Risk Evaluation and Mitigation Strategies enhanced for all extended-release/long-acting opioids as it recommends 11-2, one abstention, against approval of Zogenix’s single-entity hydrocodone product.